Phase I/II Study of Metastatic Melanoma Patients Treated with Nivolumab Who Had Progressed after Ipilimumab
Abstract The checkpoint inhibitor nivolumab is active in patients with metastatic melanoma who have failed ipilimumab. In this phase I/II study, we assessed nivolumab's safety in 92 ipilimumab-refractory patients with unresectable stage III or IV melanoma, including those who experienced grade...
Збережено в:
| Автори: | , , , , , , , , , , , , , |
|---|---|
| Формат: | Artigo |
| Мова: | Англійська |
| Опубліковано: |
2016
|
| Онлайн доступ: | https://doi.org/10.1158/2326-6066.cir-15-0193 https://cancerimmunolres.aacrjournals.org/content/canimm/4/4/345.full.pdf |
| Теги: |
Додати тег
Немає тегів, Будьте першим, хто поставить тег для цього запису!
|